Kymera Therapeutics (KYMR) Total Non-Current Liabilities (2020 - 2024)

Kymera Therapeutics (KYMR) has 5 years of Total Non-Current Liabilities data on file, last reported at $142.4 million in Q4 2024.

• On a quarterly basis, Total Non-Current Liabilities fell 21.22% year-over-year to $142.4 million in Q4 2024; TTM through Dec 2024 was $142.4 million, a 21.22% decrease from a year earlier, with the FY2024 full-year figure at $142.4 million, down 21.22% from the prior year.
• Total Non-Current Liabilities for Q4 2024 stood at $142.4 million, down from $180.8 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for KYMR reached as high as $203.2 million in Q4 2020 and fell as low as $112.7 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $153.5 million across 5 years, with a median of $149.0 million in 2023.
• Across the five-year window, Total Non-Current Liabilities fell 29.14% in 2022 and surged 60.37% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $203.2 million in 2020, then retreated by 28.05% to $146.2 million in 2021, then declined by 22.89% to $112.7 million in 2022, then jumped by 60.37% to $180.8 million in 2023, then fell by 21.22% to $142.4 million in 2024.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $142.4 million in Q4 2024, $180.8 million in Q4 2023, and $156.8 million in Q3 2023.